P&T Committee Changes
June 1, 2023The Harvard Drug Group, LLC Issues Voluntary Nationwide Recall of DronabinolCapsules USP 2.5 mg and Ziprasidone Hydrochloride Capsules 20 mg Due to LabelMix-Up
June 13, 2023June 8, 2023 - Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) has approved Vevye TM (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease. Vevye (development name CyclASol ® ) is the first and only cyclosporine solution indicated for the treatment of signs and symptoms of dry eye disease with efficacy demonstrated after 4 weeks of treatment.
Dosage is for one drop of VEVYE twice a day in each eye approximately 12 hours apart. The water-free product does not contain antimicrobial preservatives.
Dry eye disease (DED) affects millions of Americans and is one of the most common ocular surface disorders. A leading cause of DED is inflammation of the ocular surface. The chronic inflammatory nature causes progressive corneal surface damage that can lead to direct or indirect visual impairment.